Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Clin Sleep Med. 2023 Dec 1;19(12):2015-2025. doi: 10.5664/jcsm.10740.
This meta-analysis aimed to systematically assess the effects of continuous positive airway pressure (CPAP) in secondary prevention of major cardiovascular events (MACEs) in patients with moderate-to-severe obstructive sleep apnea and coronary artery disease.
PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov were searched for observational studies and randomized controlled trials that compared CPAP with usual care in patients with moderate-to-severe obstructive sleep apnea with coronary artery disease. The primary outcomes were MACEs, all-cause death, acute coronary syndrome, rehospitalization for heart failure, repeat revascularization, and arrhythmia.
A total of 11 studies (5 randomized controlled trials and 6 observational studies) with 5,410 patients reported outcomes of MACEs. Treatment with CPAP was associated with a modest risk reduction in MACEs (risk ratio [RR] 0.87, 95% confidence interval [CI] 0.78 to 0.98; = .02). Similarly, CPAP significantly reduced the risk of all-cause and cardiovascular death by 23% (RR 0.77, 95% CI 0.60 to 0.99; = .04; = 0%). Subgroup analysis revealed that CPAP adherence time ≥ 4 hours/night had a greater benefit on MACEs by 42% (RR 0.58, 95% CI 0.42 to 0.79; < .001; = 0%) and repeat revascularization by 44% (RR 0.56, 95% CI 0.34 to 0.92; = .02; = 0%). Also, CPAP had a positive effect on systolic and diastolic blood pressure.
CPAP therapy might prevent subsequent MACEs and all-cause death among patients with moderate to severe obstructive sleep apnea and concomitant coronary artery disease. CPAP use exceeding 4 hours/night may add more benefits on MACEs, repeat revascularization, and blood pressure.
Registry: PROSPERO database; Name: Effects of Continuous Positive Airway Pressure on Cardiovascular Events and Metabolic Components in Patients with Obstructive Sleep Apnea and Coronary Artery Disease; URL: https://www.crd.york.ac.uk/prospero/display_record.php?ID= CRD42020213546; Identifier: CRD42020213546.
Yang D, Li L, Dong J, Yang W, Liu Z. Effects of continuous positive airway pressure on cardiac events and metabolic components in patients with moderate to severe obstructive sleep apnea and coronary artery disease: a meta-analysis. . 2023;19(12):2015-2025.
本荟萃分析旨在系统评估中重度阻塞性睡眠呼吸暂停(OSA)合并冠状动脉疾病患者中持续气道正压通气(CPAP)在预防主要心血管不良事件(MACE)中的作用。
检索PubMed、Embase、Cochrane 图书馆和 ClinicalTrials.gov 中比较 CPAP 与中重度 OSA 合并冠状动脉疾病患者常规治疗的观察性研究和随机对照试验。主要结局为 MACE、全因死亡、急性冠状动脉综合征、心力衰竭再住院、再次血运重建和心律失常。
共纳入 11 项研究(5 项随机对照试验和 6 项观察性研究),共 5410 例患者报告了 MACE 结局。CPAP 治疗可适度降低 MACE 风险(风险比 [RR]0.87,95%置信区间 [CI]0.78 至 0.98; =.02)。同样,CPAP 可显著降低全因和心血管死亡风险 23%(RR 0.77,95% CI 0.60 至 0.99; =.04; = 0%)。亚组分析显示,CPAP 依从性时间≥4 小时/夜可使 MACE 降低 42%(RR 0.58,95% CI 0.42 至 0.79; <.001; = 0%)和再次血运重建降低 44%(RR 0.56,95% CI 0.34 至 0.92; =.02; = 0%)。此外,CPAP 对收缩压和舒张压也有积极影响。
CPAP 治疗可能预防中重度 OSA 合并冠状动脉疾病患者的后续 MACE 和全因死亡。CPAP 使用率超过 4 小时/夜可能会在 MACE、再次血运重建和血压方面带来更多获益。
PROSPERO 数据库,注册号:Effects of Continuous Positive Airway Pressure on Cardiovascular Events and Metabolic Components in Patients with Obstructive Sleep Apnea and Coronary Artery Disease;网址:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020213546;标识符:CRD42020213546。
Yang D, Li L, Dong J, Yang W, Liu Z. Effects of continuous positive airway pressure on cardiac events and metabolic components in patients with moderate to severe obstructive sleep apnea and coronary artery disease: a meta-analysis.. 2023;19(12):2015-2025.